• 1. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 2. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 3. Fast synthesis of red Li3BaSrLn3(WO4)8:Eu3+ phosphors for white LEDs under near-UV excitation by a microwave-assisted solid state reaction method and photoluminescence studies
  Bo Wei,Zhenyu Liu,Chen Xie,Shu Yang,Wentao Tang,Aiwei Gu,Wing-Tak Wong,Ka-Leung Wong J. Mater. Chem. C, 2015,3, 12322-12327
• 4. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 5. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Acyl carnitines
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty acid esters Acyl carnitines

2-Methylbutyrylcarnitine (CAS 256928-75-3): A Novel Compound in Metabolic Regulation and Therapeutic Applications

2-Methylbutyrylcarnitine, also known as CAS 256928-75-3, is a unique derivative of carnitine that has garnered significant attention in recent years for its potential role in metabolic regulation and its therapeutic implications in various physiological conditions. This compound belongs to the family of acylcarnitines, which are essential in the transport of long-chain fatty acids across the mitochondrial membrane. The molecular structure of 2-Methylbutyrylcarnitine is characterized by the acyl group derived from 2-methylbutyric acid, a branched-chain fatty acid, conjugated to the carnitine backbone. This unique structural feature distinguishes it from other acylcarnitines and may contribute to its specific biological activities.

Recent studies have highlighted the importance of 2-Methylbutyrylcarnitine in the context of mitochondrial function and energy metabolism. Research published in Cell Metabolism (2023) demonstrated that 2-Methylbutyrylcarnitine plays a critical role in the regulation of fatty acid oxidation pathways. The compound has been shown to enhance the transport of branched-chain fatty acids into mitochondria, thereby supporting the production of ATP and reducing the accumulation of toxic metabolites. This finding has significant implications for the treatment of metabolic disorders such as mitochondrial myopathy and fatty acid oxidation defects.

One of the most intriguing aspects of 2-Methylbutyrylcarnitine is its potential application in the field of neurodegenerative diseases. A 2024 study in Neuroscience reported that 2-Methylbutyrylcarnitine may mitigate the pathological effects of neuroinflammation by modulating mitochondrial dysfunction in neuronal cells. The compound was found to reduce oxidative stress and promote the clearance of misfolded proteins, which are hallmark features of conditions such as Alzheimer's disease and Parkinson's disease. These findings suggest that 2-Methylbutyrylcarnitine could be a promising candidate for the development of novel therapeutic strategies targeting neurodegenerative disorders.

In addition to its role in metabolic and neurological contexts, 2-Methylbutyrylcarnitine has also been investigated for its potential in cancer therapy. A 2023 preclinical study published in Cancer Research explored the anti-tumor effects of 2-Methylbutyrylcarnitine in breast cancer models. The study revealed that the compound could inhibit the proliferation of cancer cells by inducing apoptosis and suppressing the activation of oncogenic signaling pathways. These results highlight the potential of 2-Methylbutyrylcarnitine as an adjunctive therapy in cancer treatment, particularly in combination with traditional chemotherapeutic agents.

The synthesis of 2-Methylbutyrylcarnitine (CAS 256928-75-3) involves a series of chemical reactions that are well-documented in the literature. The process typically begins with the esterification of 2-methylbutyric acid to form the corresponding acyl group, which is then conjugated to the carnitine molecule. This reaction is catalyzed by specific enzymes, such as acyltransferases, which ensure the precise formation of the acylcarnitine structure. The purity and stability of the final product are critical factors in its application, as impurities can affect its biological activity and safety profile.

Recent advances in analytical techniques have enabled researchers to better characterize the properties of 2-Methylbutyrylcarnitine. High-resolution mass spectrometry and nuclear magnetic resonance (NMR) spectroscopy have been instrumental in confirming the molecular structure and identifying potential metabolites. These techniques have also facilitated the quantification of 2-Methylbutyrylcarnitine in biological samples, providing insights into its pharmacokinetic behavior and tissue distribution. Such data are essential for understanding the compound's therapeutic potential and optimizing its use in clinical settings.

The therapeutic potential of 2-Methylbutyrylcarnitine is further supported by its role in the regulation of lipid metabolism. A 2022 study in Journal of Lipid Research found that 2-Methylbutyrylcarnitine could modulate the activity of key enzymes involved in lipid synthesis and breakdown. This regulatory effect may have implications for the management of metabolic syndromes, including obesity and type 2 diabetes. The compound's ability to enhance fatty acid oxidation while suppressing lipogenesis could represent a novel approach to addressing these conditions.

Despite the promising findings, the clinical application of 2-Methylbutyrylcarnitine remains in its early stages. Challenges such as the need for high-dose formulations and the potential for side effects must be addressed before widespread use can be considered. Ongoing clinical trials are evaluating the safety and efficacy of 2-Methylbutyrylcarnitine in various patient populations. These trials are critical for translating the laboratory findings into practical therapeutic applications.

In conclusion, 2-Methylbutyrylcarnitine (CAS 256928-75-3) is a compound with significant potential in the fields of metabolic, neurological, and oncological research. Its unique structural features and biological activities suggest that it could play a pivotal role in the development of new therapies for a range of diseases. As research in this area continues to evolve, the compound may become an important tool in the treatment of complex medical conditions. Further studies are needed to fully elucidate its mechanisms of action and to optimize its therapeutic applications.

For researchers and clinicians interested in exploring the potential of 2-Methylbutyrylcarnitine, staying updated with the latest studies and clinical trials is essential. Collaboration between different scientific disciplines will be crucial in advancing our understanding of this compound and its applications. As the field of acylcarnitine research continues to grow, 2-Methylbutyrylcarnitine may emerge as a key player in the quest for innovative therapeutic solutions.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)